{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T04:40:01Z","timestamp":1754109601175,"version":"3.41.2"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Antipsychotic drugs are still widely prescribed to control various severe neuropsychiatric symptoms in the elderly and dementia patients although they are off-label use in the United States. However, clinical practice shows greater side effects and lower efficacy of antipsychotics for this vulnerable population and the mechanisms surrounding this aged-related sensitivity are not well understood. Our previous studies have shown that aging-induced epigenetic alterations may be involved in the increasing severity of typical antipsychotic haloperidol induced side effects in aged mice. Still, it is unknown if similar epigenetic mechanisms extend to atypical antipsychotics, which are most often prescribed to dementia patients combined with severe neuropsychiatric symptoms. In this study, we report that atypical antipsychotic risperidone also causes increased motor side effect behaviors in aged mice and 5xFAD mice. Histone deacetylase (HDAC) inhibitor Valproic Acid and Entinostat can mitigate the risperidone induced motor side effects. We further showed besides D2R, reduced expression of 5-HT2A, one of the primary atypical antipsychotic targets in the striatum of aged mice that are also mitigated by HDAC inhibitors. Finally, we demonstrate that specific histone acetylation mark H3K27 is hypoacetylated at the <jats:italic>5htr2a<\/jats:italic> and <jats:italic>Drd2<\/jats:italic> promoters in aged mice and can be reversed with HDAC inhibitors. Our work here establishes evidence for a mechanism where aging reduces expression of 5-HT2A and D2R, the key atypical antipsychotic drug targets through epigenetic alteration. HDAC inhibitors can restore 5-HT2A and D2R expression in aged mice and decrease the motor side effects in aged and 5xFAD mice.<\/jats:p>","DOI":"10.3389\/fpsyt.2022.1020831","type":"journal-article","created":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T15:23:58Z","timestamp":1673018638000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Histone deacetylase inhibitors mitigate antipsychotic risperidone-induced motor side effects in aged mice and in a mouse model of Alzheimer\u2019s disease"],"prefix":"10.3389","volume":"13","author":[{"given":"Guadalupe","family":"Rodriguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel W.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"McClarty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janitza","family":"Montalvo-Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaoling","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Savio","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2217\/nmt-2019-0036","article-title":"Antipsychotics in the management of behavioral and psychological symptoms of dementia: maximizing gain and minimizing harm.","volume":"10","author":"Tampi","year":"2020","journal-title":"Neurodegener Dis Manag."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1007\/s12325-022-02075-8","article-title":"Comparative outcomes of commonly used off-label atypical antipsychotics in the treatment of dementia-related psychosis: a network meta-analysis.","volume":"39","author":"Yunusa","year":"2022","journal-title":"Adv Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1111\/jcpt.13423","article-title":"Drug-related problems of antipsychotics in treating delirium among elderly patients: a real-world observational study.","volume":"46","author":"Jenraumjit","year":"2021","journal-title":"J Clin Pharm Ther."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25245789","article-title":"Comprehensive review on Alzheimer\u2019s disease: causes and treatment.","volume":"25","author":"Breijyeh","year":"2020","journal-title":"Molecules."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00269-y","article-title":"Alzheimer disease.","volume":"7","author":"Knopman","year":"2021","journal-title":"Nat Rev Dis Primers."},{"key":"B6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1177\/153331750602100209","article-title":"Management of aggression, agitation, and psychosis in dementia: focus on atypical antipsychotics.","volume":"21","author":"Aupperle","year":"2006","journal-title":"Am J Alzheimers Dis Other Demen."},{"key":"B7","first-page":"344","article-title":"Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals.","volume":"155","author":"Volkow","year":"1998","journal-title":"Am J Psychiatry."},{"key":"B8","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0197-4580(00)00149-4","article-title":"Age-related dopamine D2\/D3 receptor loss in extrastriatal regions of the human brain.","volume":"21","author":"Kaasinen","year":"2000","journal-title":"Neurobiol Aging."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","article-title":"Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.","volume":"294","author":"Schneider","year":"2005","journal-title":"JAMA."},{"key":"B10","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1176\/appi.ajp.2012.12030342","article-title":"Atypical antipsychotic use in patients with dementia: managing safety concerns.","volume":"169","author":"Steinberg","year":"2012","journal-title":"Am J Psychiatry."},{"key":"B11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40501-018-0134-4","article-title":"Epigenetic alterations impact on antipsychotic treatment in elderly patients.","volume":"5","author":"McClarty","year":"2018","journal-title":"Curr Treat Options Psychiatry."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00716-z","article-title":"Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors.","volume":"8","author":"Sykes","year":"2017","journal-title":"Nat Commun."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1038\/npp.2013.346","article-title":"HDAC inhibitors restore the capacity of aged mice to respond to haloperidol through modulation of histone acetylation.","volume":"39","author":"Montalvo-Ortiz","year":"2014","journal-title":"Neuropsychopharmacology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1007\/s00213-017-4629-2","article-title":"Histone deacetylase inhibitors reverse age-related increases in side effects of haloperidol in mice.","volume":"234","author":"Montalvo-Ortiz","year":"2017","journal-title":"Psychopharmacology."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01109","article-title":"The hyperactivity-impulsivity-irritiability-disinhibition-aggression-agitation domain in Alzheimer\u2019s disease: current management and future directions.","volume":"10","author":"Keszycki","year":"2019","journal-title":"Front Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.674745","article-title":"Dose effects of histone deacetylase inhibitor tacedinaline (CI-994) on antipsychotic haloperidol-induced motor and memory side effects in aged mice.","volume":"15","author":"McClarty","year":"2021","journal-title":"Front Neurosci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1176\/appi.ajp.2012.12030386","article-title":"Association between older age and more successful aging: critical role of resilience and depression.","volume":"170","author":"Jeste","year":"2013","journal-title":"Am J Psychiatry."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.2174\/1568026616666160608084834","article-title":"Dopamine targeting drugs for the treatment of schizophrenia: past, present and future.","volume":"16","author":"Li","year":"2016","journal-title":"Curr Top Med Chem."},{"key":"B19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1177\/070674370204700106","article-title":"Atypical antipsychotics: mechanism of action.","volume":"47","author":"Seeman","year":"2002","journal-title":"Can J Psychiatry."},{"key":"B20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/JCP.0b013e3182a6096e","article-title":"Use and safety of antipsychotics in behavioral disorders in elderly people with dementia.","volume":"34","author":"Gareri","year":"2014","journal-title":"J Clin Psychopharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.pnpbp.2003.10.006","article-title":"Adverse effects of risperidone and haloperidol treatment in schizophrenia.","volume":"28","author":"Yen","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.713726","article-title":"Comprehensive evaluation of the 5XFAD mouse model for preclinical testing applications: a MODEL-AD study.","volume":"13","author":"Oblak","year":"2021","journal-title":"Front Aging Neurosci."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.0828","article-title":"Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis.","volume":"2","author":"Yunusa","year":"2019","journal-title":"JAMA Netw Open."},{"key":"B24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/00131746-200701000-00003","article-title":"EPS profiles: the atypical antipsychotics are not all the same.","volume":"13","author":"Weiden","year":"2007","journal-title":"J Psychiatr Pract."},{"key":"B25","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/PL00005482","article-title":"Theory and method in the quantitative analysis of \u201cimpulsive choice\u201d behaviour: implications for psychopharmacology.","volume":"146","author":"Ho","year":"1999","journal-title":"Psychopharmacology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/sj.npp.1300940","article-title":"Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties.","volume":"31","author":"Bardin","year":"2006","journal-title":"Neuropsychopharmacology."},{"key":"B27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejphar.2011.01.018","article-title":"Antipsychotic-induced catalepsy is attenuated in mice lacking the M4 muscarinic acetylcholine receptor.","volume":"656","author":"Fink-Jensen","year":"2011","journal-title":"Eur J Pharmacol."},{"key":"B28","first-page":"564","article-title":"Effect of tribulus terrestris on haloperidol-induced catalepsy in mice.","volume":"76","author":"Nishchal","year":"2014","journal-title":"Indian J Pharm Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"ENEURO.488","DOI":"10.1523\/ENEURO.0488-19.2020","article-title":"An open source automated bar test for measuring catalepsy in rats.","volume":"7","author":"Luciani","year":"2020","journal-title":"eNeuro."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1080\/00207450902984002","article-title":"Rotarod impairment: catalepsy-like screening test for antipsychotic side effects.","volume":"119","author":"Kirschbaum","year":"2009","journal-title":"Int J Neurosci."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00596","article-title":"The use of risperidone in behavioral and Psychological symptoms of dementia: a review of pharmacology, clinical evidence, regulatory approvals, and off-label use","volume":"11","author":"Yunusa","year":"2020","journal-title":"Front Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2165\/00002512-200623120-00002","article-title":"Adverse effects of atypical antipsychotics in the elderly: a review.","volume":"23","author":"Gareri","year":"2006","journal-title":"Drugs Aging."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.2147\/CIA.S63942","article-title":"Use of atypical antipsychotics in the elderly: a clinical review.","volume":"9","author":"Gareri","year":"2014","journal-title":"Clin Interv Aging."},{"key":"B34","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1001\/jamapsychiatry.2014.3018","article-title":"Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm.","volume":"72","author":"Maust","year":"2015","journal-title":"JAMA Psychiatry."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013304.pub2","article-title":"Antipsychotics for agitation and psychosis in people with Alzheimer\u2019s disease and vascular dementia.","volume":"12","author":"M\u00fchlbauer","year":"2021","journal-title":"Cochrane Database Syst Rev."},{"key":"B36","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/s002130000466","article-title":"Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats.","volume":"150","author":"Wadenberg","year":"2000","journal-title":"Psychopharmacology."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1046\/j.0953-816x.2001.01759.x","article-title":"Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A(2A) receptors in the caudate-putamen of rats.","volume":"14","author":"Hauber","year":"2001","journal-title":"Eur J Neurosci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0893-133X(01)00261-5","article-title":"Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects.","volume":"25","author":"Wadenberg","year":"2001","journal-title":"Neuropsychopharmacology."},{"key":"B39","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/hup.476","article-title":"Efficacy of nefazodone in the treatment of neuroleptic induced extrapyramidal side effects: a double-blind randomised parallel group placebo-controlled trial.","volume":"18","author":"Wynchank","year":"2003","journal-title":"Hum Psychopharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0079-6123(08)00909-6","article-title":"In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.","volume":"172","author":"Meltzer","year":"2008","journal-title":"Prog Brain Res."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-019-2304-3","article-title":"Making decisions about antipsychotics: a qualitative study of patient experience and the development of a decision aid.","volume":"19","author":"Kaar","year":"2019","journal-title":"BMC Psychiatry."},{"key":"B42","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/pcn.12242","article-title":"Psychopharmacology of atypical antipsychotic drugs: from the receptor binding profile to neuroprotection and neurogenesis.","volume":"69","author":"Kusumi","year":"2015","journal-title":"Psychiatry Clin Neurosci."},{"key":"B43","first-page":"390","article-title":"The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs.","volume":"25","author":"Meltzer","year":"1989","journal-title":"Psychopharmacol Bull."},{"key":"B44","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0168-9525(03)00115-X","article-title":"The diverse functions of histone acetyltransferase complexes.","volume":"19","author":"Carrozza","year":"2003","journal-title":"Trends Genet."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.3390\/ph3092751","article-title":"Clinical toxicities of histone deacetylase inhibitors.","volume":"3","author":"Subramanian","year":"2010","journal-title":"Pharmaceuticals."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.1020831\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T15:24:03Z","timestamp":1673018643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.1020831\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,6]]},"references-count":45,"alternative-id":["10.3389\/fpsyt.2022.1020831"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2022.1020831","relation":{},"ISSN":["1664-0640"],"issn-type":[{"type":"electronic","value":"1664-0640"}],"subject":[],"published":{"date-parts":[[2023,1,6]]},"article-number":"1020831"}}